PMID- 30814769
OWN - NLM
STAT- MEDLINE
DCOM- 20190730
LR  - 20220408
IS  - 1986-5961 (Electronic)
IS  - 0350-199X (Print)
IS  - 0350-199X (Linking)
VI  - 72
IP  - 6
DP  - 2018 Dec
TI  - Impact of Different Types of Statins on Clinical Outcomes in Patients 
      Hospitalized for Ischemic Heart Failure.
PG  - 401-405
LID - 10.5455/medarh.2018.72.401-405 [doi]
AB  - INTRODUCTION: The effect of statins on risk of heart failure (HF) hospitalization 
      and lethal outcome remains dubious. AIM: To investigate whether statin therapy 
      improves clinical outcomes in patients hospitalized for ischemic heart failure 
      (HF), to compare the efficacy of lipophilic and hydrophilic statins and to 
      investigate which statin subtype provides better survival and other outcome 
      benefits. MATERIAL AND METHODS: Total amount of 155 patients in the study were 
      admitted to the Clinic for Cardiology, Rheumatology and Vascular diseases in 
      Clinical Center University of Sarajevo in the period from January 2014- December 
      2017. Inclusion criteria was HF caused by ischemic coronary artery disease upon 
      admission. For each patient the following data were obtained: gender, age, 
      comorbidities and medications on discharge. New York Heart Association (NYHA) 
      class for heart failure was determined by physician evaluation and left ventricle 
      ejection fraction (LVEF) was determined by echocardiography. The patients were 
      followed for a period of two years. Outcome points were: rehospitalization, 
      in-hospital death, mortality after 6 months, 1 year and 2 years. All-cause 
      mortality included cardiovascular events or worsening heart failure. RESULTS: 
      Overall, 58.9% of HF patients received statin therapy, with 33.9% patients 
      receiving atorvastatin and 25.0% rosuvastatin therapy. The most frequent 
      rehospitalization was in patients without statin therapy (66.7%), followed by 
      patients on rosuvastatin (64.1%), and atorvastatin (13.2%), with statistically 
      significant difference p = 0.001 between the groups. Mortality after 6 months, 1 
      year and 2 years was the most frequent in patients without statin therapy with a 
      statistically significant difference (p = 0.001). Progression of HF accounted for 
      31.7% of mortality in patients without statin therapy, 12.8% in patients on 
      rosuvastatin therapy and 3.8% in patients on atorvastatin therapy (p = 0.004). 
      CONCLUSION: Lipophilic statin therapy is associated with substantially better 
      long-term outcomes in patients with HF.
FAU - Zvizdic, Faris
AU  - Zvizdic F
AD  - Department for Cardiology, Clinic for Heart, Vascular Diseases and Rheumatology, 
      Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
FAU - Godinjak, Amina
AU  - Godinjak A
AD  - Department for Emergency Medicine, Clinical Center University of Sarajevo, 
      Sarajevo, Bosnia and Herzegovina.
FAU - Durak-Nalbantic, Azra
AU  - Durak-Nalbantic A
AD  - Department for Cardiology, Clinic for Heart, Vascular Diseases and Rheumatology, 
      Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
FAU - Rama, Admir
AU  - Rama A
AD  - Bahceci IVF Center Sarajevo, Sarajevo, Bosnia and Herzegovina.
FAU - Iglica, Amer
AU  - Iglica A
AD  - Department for Cardiology, Clinic for Heart, Vascular Diseases and Rheumatology, 
      Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
FAU - Vucijak-Grgurevic, Marina
AU  - Vucijak-Grgurevic M
AD  - Department for Cardiology, Clinic for Heart, Vascular Diseases and Rheumatology, 
      Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
FAU - Sokolovic, Sekib
AU  - Sokolovic S
AD  - Department for Cardiology, Clinic for Heart, Vascular Diseases and Rheumatology, 
      Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
LA  - eng
PT  - Journal Article
PL  - Bosnia and Herzegovina
TA  - Med Arch
JT  - Medical archives (Sarajevo, Bosnia and Herzegovina)
JID - 101635337
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
MH  - Aged
MH  - Comorbidity
MH  - Disease Progression
MH  - Female
MH  - Heart Failure/*drug therapy/mortality/physiopathology
MH  - Hospitalization
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase 
      Inhibitors/classification/pharmacology/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Treatment Outcome
MH  - Ventricular Function, Left/*drug effects/physiology
PMC - PMC6340614
OTO - NOTNLM
OT  - heart failure
OT  - statins
OT  - treatment
EDAT- 2019/03/01 06:00
MHDA- 2019/07/31 06:00
PMCR- 2018/12/01
CRDT- 2019/03/01 06:00
PHST- 2019/03/01 06:00 [entrez]
PHST- 2019/03/01 06:00 [pubmed]
PHST- 2019/07/31 06:00 [medline]
PHST- 2018/12/01 00:00 [pmc-release]
AID - 10.5455/medarh.2018.72.401-405 [doi]
PST - ppublish
SO  - Med Arch. 2018 Dec;72(6):401-405. doi: 10.5455/medarh.2018.72.401-405.